News Releases

RNS Number : 2271I MaxCyte, Inc. 01 December 2022       MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director       Rockville, MD , 1 December, 2022 :   MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell - engineering focused company providing enabling platform technologies to

RNS Number : 0603G MaxCyte, Inc. 11 November 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing

RNS Number : 8941F MaxCyte, Inc. 10 November 2022   MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2022   ROCKVILLE, MD , November 10, 2022 -   MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform

RNS Number : 8908F MaxCyte, Inc. 10 November 2022            MaxCyte Reports Third Quarter 2022 Financial Results   22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022   Reiterates 2022 Revenue Guidance   ROCKVILLE, MD , November 10, 2022   - MaxCyte, Inc.

22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the

ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support

RNS Number : 0728F MaxCyte, Inc. 02 November 2022   MaxCyte to Participate in Upcoming Investor Conferences ROCKVILLE, MD , November 2, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,

RNS Number : 8870E MaxCyte, Inc. 01 November 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 November 2022 :       MaxCyte (LSE: MXCT),   a leading commercial cell - engineering company focused on providing enabling platform technologies to

RNS Number : 1498D MaxCyte, Inc. 17 October 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development